TenNor and Janssen to Collaborate on Lung Disease Treatments

TenNor Therapeutics ( Suzhou ) announced a research collaboration with Janssen Pharma that will use TenNor's drug conjugation platform to discover new therapies for the treatment of nontuberculous mycobacteria (NTM) diseases. NTM diseases require treatment by multiple antibiotics administered for a duration of more than two years. Existing therapies are not always effective and may cause side effects. The goal of the collaboration is to discover novel therapies for NTM diseases that shorten the duration of treatment with a better safety and efficacy profile. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.